Landmark Long-Term Remission Achieved with ICG318, a BCMA-CD19 Armored Compound CAR T-cell Therapy, in Refractory Systemic Lupus Erythematosus/Lupus Nephritis with Follow-up Approaching 6 Years

Transplantation and Cellular Therapy 2026

View at publisher
Authors: Ming Hong, Mingxia Wang, Ronghao Zeng, Ling Ding, Shanzhi He, Ting Lan, Vincent M. DeStefano, Masayuki Wada, Kevin G. Pinz, Jennifer E. Chow, Byeong Hyeok Choi, Nabil G. Hagag
+9 more Min Wang, Yu Ma, Jing Luo, Yingwen Liang, Ziji Lu, Wenli Zhang, Shihao Ding, Yupo Ma, Weijia Wang
DOI: 10.1016/j.jtct.2025.12.061
Cited by: 1

Fields of Study & Subjects

CAR-T cell therapy research Biomedical Ethics and Regulation Systemic Lupus Erythematosus Research

Publication details

Journal / source
Transplantation and Cellular Therapy
Publisher
Elsevier BV
Volume
32
Issue
2
Pages
S38–S38
Publication date
1 February 2026
Language
EN